Past Webinars

Immunohistochemistry (IHC) remains central to precision oncology – but how much does it really influence the final molecular profile?

In this educational webinar, we explore how IHC can make or break a patient’s Caris MI Profile® – and what happens when IHC results interact with whole exome sequencing (WES) and whole transcriptome sequencing (WTS) findings in complex cancers.

Through practical case examples, you’ll see how IHC drives real clinical decisions – reducing diagnostic uncertainty and helping guide therapy selection where it matters most.

As precision oncology expands, clinicians increasingly encounter clonal hematopoiesis findings that fall outside traditional diagnostic frameworks. This webinar draws directly from the published TET2-mutant clonal hematopoiesis study to examine prevalence, biological context, and potential clinical implications. Attendees will gain perspective on how comprehensive molecular profiling—central to Caris Life Sciences’ initiatives—can help differentiate incidental findings from clinically meaningful signals and guide appropriate next steps in patient management.

This recorded webinar reviews the clinical use of cResponse, a solid tumour functional testing platform based on ex-vivo organ cultures. The speakers discuss how cResponse can be used to assess treatment sensitivity and resistance, with a focus on real-world application. 

The session includes an overview of the cResponse platform, clinical use cases, and expert discussion with Professor Ravid Straussman, Dr Jonathan Krell, and chair Professor Tobi Arkneau.’

Several emerging therapies have identified surface proteins as targets. Caris Life Sciences is a market leader in offering immunohistochemistry for emerging oncology biomarkers such as Claudin 18.2, FGFR2b and MET. In this webinar, presenters will review Caris’ approach for evaluating novel biomarkers for inclusion on our comprehensive assay and review our latest offerings and upcoming additions.